öλÔÓéÀֵǼÈë¿ÚÏÂÔØ

µ¼Ê¦ÐÕÃû£º¹ÜÓÖ·É
ÐÔ±ð£º
ÈËÆøÖ¸Êý£º82

ËùÊôԺУ£º´óÁ¬Ò½¿Æ´óѧ
ËùÊôԺϵ£ºÒ½Ñ§¿ÆѧÑо¿Ôº
Ö°³Æ£º½ÌÊÚ
µ¼Ê¦ÀàÐÍ£º²©µ¼
ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£º
Ñо¿ÁìÓò£º 1£®´úлÐÔºËÊÜÌå¼Ò×壨PPARs¡¢LXRs¡¢FXRsºÍPXRs£©ÔÚ´úлÐÔ¼²²¡ÌرðÊÇÌÇÄò²¡¡¢... [Õ¹¿ª]


Ñо¿ÁìÓò£º 1£®´úлÐÔºËÊÜÌå¼Ò×壨PPARs¡¢LXRs¡¢FXRsºÍPXRs£©ÔÚ´úлÐÔ¼²²¡ÌرðÊÇÌÇÄò²¡¡¢Ö¬·¾¸Î¡¢¸ß֬Ѫ֢¡¢¸ßѪѹ·¢²¡¼°ÖÎÁÆÖеÄ×÷Óã»2£®Ç°ÁÐÏÙËØE2£¨PGE2£©µÄÉúÎïºÏ³Éµ÷½Ú¼°Æä×÷Ϊ¼²²¡£¨·¢ÈÈ¡¢ÌÛÍ´¡¢ÉúÖ³¼²»¼¡¢¸ßѪѹ¡¢Ñ×Ö¢ºÍÉöÔ༲²¡£©ÖÎÁưеãµÄÑо¿£»3£®ÌÇÄò²¡¼°Æä²¢·¢Ö¢£¬ÌرðÊÇÌÇÄò²¡Éö²¡µÄ·¢²¡»úÖÆ¡¢Ô¤·À¡¢ÔçÆÚÕï¶Ï¡¢·Ö×Ó±êÖ¾ÎïµÄ·¢ÏÖ¼°ÖÎÁÆ¡£ [ÊÕÆð]




ͨѶ·½Ê½ :
°ì¹«µç»°£º**
µç×ÓÓʼþ£ºluheyuan.0123@163.com


¸öÈ˼òÊö :
¹ÜÓַɽÌÊÚ£¬²©Ê¿Éúµ¼Ê¦£¬´óÁ¬Ò½¿Æ´óѧ¸±Ð£³¤¡¢´óÁ¬Ò½¿Æ´óѧҽѧ¿ÆѧÑо¿ÔºÔº³¤¡£±±¾©Ò½¿Æ´óѧ£¨ÏÖΪ±±¾©´óѧҽѧ²¿£©Ò½Ñ§²©Ê¿£¬ÃÀ¹úVanderbilt´óѧҽѧԺÖúÀí½ÌÊÚ£¬ÀúÈα±¾©´óѧ»ù´¡Ò½Ñ§Ôº¸±Ôº³¤¡¢ÉúÀíÓ벡ÀíÉúÀíѧϵÖ÷ÈΡ¢ÉîÛÚ´óѧҽѧ²¿Ö÷ÈΡ£½ÌÓý²¿³¤½­Ñ§ÕßÌØƸ½ÌÊÚ¡¢¹ú¼Ò½Ü³öÇàÄê»ù½ð»ñµÃÕß¡¢¿Æ¼¼²¿973¡°Ö¬·¾¸Î¼°¸ß֬Ѫ֢·ÀÖΡ±ÖØ´ó»ù´¡Ñо¿¼Æ»®Ê×ϯ¿Æѧ¼Ò¡¢ÈËʲ¿°ÙǧÍòÈ˲Ź¤³Ì¡°ÓÐÍ»³ö¹±Ï×ÖÐÇàÄêר¼Ò¡±¡¢¹úÎñÔºÕþ¸®ÌØÊâ½òÌù»ñµÃÕß¡¢¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðίҽѧ²¿¡¢ÉúÃü¿Æѧ²¿×Éѯ×éר¼Ò¡£³¤ÆÚ´ÓÊ´úлÐÔºËÊÜÌ壨PPARs¡¢LXRs¡¢FXRs ºÍ PXRs£©ÔÚ´úлÐÔ¼²²¡ÌرðÊÇÌÇÄò²¡¡¢¸ßѪѹ¡¢Ö¬·¾¸Î·¢²¡¼°ÖÎÁÆÖеÄ×÷Óã»Ç°ÁÐÏÙËØE2£¨PGE2£©µÄÉúÎïºÏ³Éµ÷½Ú¼°Æä×÷Ϊ¼²²¡£¨·¢ÈÈ¡¢ÌÛÍ´¡¢ÉúÖ³¼²»¼¡¢¸ßѪѹ¡¢Ñ×Ö¢ºÍÉöÔ༲²¡£©ÖÎÁưеãµÄÑо¿µÈ¡£Ñо¿Êܵ½ÃÀ¹ú¹úÁ¢ÎÀÉúÑо¿Ôº(NIH-NIDDK RO1)¡¢¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðί½Ü³öÇàÄê¿Æѧ»ù½ð¡¢ÖØ´óÏîÄ¿¡¢Öصã»ù½ð¡¢¿Æ¼¼²¿973ÏîÄ¿µÄ×ÊÖú¡£ÔÚNature Medicine¡¢J Clin Invest¡¢Diabetes¡¢Hepatology¡¢PNAS µÈ¹ú¼ÊÖªÃûÔÓÖ¾ÉÏ·¢±í140ÓàƪԭÖøÎÄÕ¡£¡°Ê®¶þÎ塱ÆÕͨ¸ßУ¹ú¼Ò¹æ»®½Ì²Ä¡¶Ò½Ñ§ÉúÀíѧ¡·Ö÷±à£¬2013ÄêÉîÛÚÊйú¼Ò¼¶Áì¾üÈ˲Å£¬2015Äê´óÁ¬Êйú¼Ò¼¶Áì¾üÈ˲Å£¬ÈëÑ¡¡°2014Äê¡¢2015¡¢2016ÄêÖйú¸ß±»ÒýѧÕß°ñµ¥¡±Ò½Ñ§ÁìÓòµÚ15Ãû¡¢18Ãû¡¢18Ãû¡£

¿ÆÑй¤×÷ :
ÔÚÑÐÏîÄ¿£º1.¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÖØ´óÏîÄ¿£¨×Ó¿ÎÌ⣩£¬¡°ÌÇ´úлÎÈ̬µ÷½Ú»ùÒòµÄת¼¼°×ªÂ¼ºóµ÷¿Ø»úÖÆ¡±£¬ÏîÄ¿¸ºÔðÈË£»2.¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðίÖØ´óÑо¿¼Æ»®ÖصãÖ§³ÖÏîÄ¿£¬¡°Ç°ÁÐÏÙËØE2ÊÜÌåEP4ÔÚѪ¹ÜÎÈ̬ά³Ö¼°ÖØËÜÖеÄ×÷Óá±£¬ÏîÄ¿¸ºÔðÈË£»3.¸ß²ã´ÎÈ˲Ŵ´ÐÂÖ§³Ö¼Æ»®£¬¡°ÖØ´ó´úлÐÔ¼²²¡·ÀÖεÄÓ¦ÓÃÑо¿¡±£¬ÏîÄ¿¸ºÔðÈË¡£
´ú±íÐÔÎÄÕ£º
1.Zhang X, Huang S, Gao M, Liu J, Jia X, Du S, Han Q, Zheng S, Gustafsson J?, Guan Y*. Farnesoid X receptor (FXR) gene deficiency impairs urine concentration in mice. Proc Natl Acad Sci U S A. 2014 Feb 11111(6):2277-82.
2.Wang C, Chi Y, Li J, Li S, Su W, Jia S, Chen Z, Miao Y, Du S, Zhang X, Zhou Y, Wu W, Zhu M, Wang Z, Yang H, Xu G, Wang S, Yang J £¬Guan Y*. FAM3A activates PI3K p110a/Akt signaling to ameliorate hepatic gluconeogenesis and lipogenesis. Hepatology 201459:1779-90.
3.Su W, Wang Y, Jia X, Wu W, Li L, Tian X, Li S, Wang C, Xu H, Cao J, Han Q, Xu S, Chen Y, Zhong Y, Zhang X, Liu P, Gustafsson J?, Guan Y*. Comparative proteomic study reveals 17¦Â-HSD13 as a pathogenic protein in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A. 2014 Aug 5111(31):11437-42.
4.Gao M, Cao R, Du S, Jia X, Zheng S, Huang S, Han Q, Liu J, Zhang X, Miao Y, Kang J, Gustafsson J?, Guan Y*. Disruption of prostaglandin E2 receptor EP4 impairs urinary concentration via decreasing aquaporin 2 in renal collecting ducts. Proc Natl Acad Sci U S A. 2015 Jul 7112(27):8397-402.
5.Xu H, Fu JL, Miao YF, Wang CJ, Han QF, Li S, Huang SZ, Du SN, Qiu YX, Yang JC, Gustafsson JA, Breyer RM, Zheng F, Wang NP, Zhang XY, Guan Y*. Prostaglandin E2 receptor EP3 regulates both adipogenesis and lipolysis in mouse white adipose tissue. J Mol Cell Biol. 2016 Dec8(6):518-29.